ArticleTherapeutic advances in neurological disorders2026
Complement C5 inhibitors as add-on rescue treatment in severe AQP4-antibody neuromyelitis optica spectrum disorder attacks: a case series and literature review.
Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute attacks of aquaporin-4 antibody neuromyelitis optica spectrum disorder (AQP4-Ab NMOSD) are typically managed with intravenous methylprednisolone, with therapeutic plasma exchange (PLEX) reserved for severe episodes. Despite these interventions, a subset of patients fails to respond and may sustain significant neurological disability. Complement C5 inhibitors, currently approved for long-term relapse prevention, have recently gained attention as a potential rescue therapy by rapidly inhibiting the terminal complement cascade, thus preventing downstream astrocytic injury. We report three patients with AQP4-Ab severe optic neuritis refractory to IV methylprednisolone and PLEX who demonstrated significant clinical improvement following administration of C5 inhibitors during the acute attack phase. Case 1 (right optic neuritis) and Case 3 (bilateral optic neuritis) received eculizumab, achieving near-complete and complete recovery of visual acuity, respectively. Both patients subsequently transitioned to rituximab within 8 weeks after their fourth weekly eculizumab infusion, while on a moderate dose of prednisolone. Case 2 (left optic neuritis) received ravulizumab, achieving partial visual recovery, and was continued on maintenance ravulizumab. Meningococcal prophylaxis with penicillin V was administered for all three patients. A literature review identified 10 publications utilising C5 inhibitors as acute attack therapies, totalling 31 cases, including our present series. Of these, 30 patients (97%) experienced neurological improvement within 4 weeks, with 28 (90%) showing improvement within the first week. Complete or near-complete recovery was observed in 42% of patients, while 55% achieved partial recovery, and one patient (3%) had no recovery. Patients achieving complete or near-complete recovery received C5 inhibitors significantly earlier than those with partial or no recovery (median 15.0 vs 24.0 days from symptom onset,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.